Q-omics provides the consensus-scored RPS11 profile across patient tissues and cancer cell-line models. RPS11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS11 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPS11 protein abundance shows 18,542 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight ACC, KIRC, and COAD as cancer lineages where RPS11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS11 survival associations across molecular data types. RPS11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS11 RNA expression–survival associations across cancer types. High RPS11 expression shows unfavorable associations in ACC, KIRP, LIHC and LUAD, but favorable associations in UVM and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS11 RNA expression.
This table summarizes RPS11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPS11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS11 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, KIRP and CHOL. The KIRC box plot shows higher RPS11 RNA expression in tumor versus normal tissue (log2 FC = +1.041, t-test p < 0.001).
This table shows molecular features associated with RPS11 in patient tissues and cancer cell lines. In patient samples, RPS11 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and PANCREAS.
